Description
Tirzepatide is a first‑in‑class dual incretin receptor agonist that activates both the glucose‑dependent insulinotropic polypeptide receptor (GIPR) and the glucagon‑like peptide‑1 receptor (GLP‑1R). This “twincretin” mechanism produces synergistic metabolic effects that surpass those of GLP‑1–only agonists.




